<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24678" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Malignant Melanoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Heistein</surname>
            <given-names>Jonathan B.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Acharya</surname>
            <given-names>Utkarsh</given-names>
          </name>
          <aff>Dana Farber Cancer Institute / Brigham</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukkamalla</surname>
            <given-names>Shiva Kumar R.</given-names>
          </name>
          <aff>Presbyterian Healthcare Services</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Heistein declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Utkarsh Acharya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24678.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Melanoma is a malignancy derived from&#x000a0;the malignant transformation of melanocytes. Melanocytes are derived from the neural crest. Therefore, melanomas, although they arise from the skin, can develop in other locations where neural crest cells migrate, such as the gastrointestinal tract and brain. The 5-year relative survival rate for patients with stage 0 melanoma or melanoma-in-situ is 97%, compared to 30% for those with stage IV disease. Once a suspicious skin lesion is identified, a biopsy must be performed to confirm the diagnosis of melanoma. An excisional biopsy is the preferred biopsy modality. Melanoma treatment typically involves wide local excision, Mohs micrographic surgery, digital amputations, or adjuvant therapy depending on tumor location, depth, ulceration, lymph node involvement, and metastasis.&#x000a0;</p>
        <p>This activity for healthcare professionals is designed to enhance the learner's competence when managing malignant melanoma, equipping them with updated knowledge, skills, and strategies for timely identification, effective interventions, prevention, and improved care coordination, leading to better patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the pathophysiology of malignant melanoma.</p></list-item><list-item><p>Interpret diagnostic studies recommended for malignant melanoma.</p></list-item><list-item><p>Implement treatment strategies for various stages of nonmetastatic malignant melanoma.</p></list-item><list-item><p>Identify the role of the interprofessional team in managing a patient with malignant melanoma.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24678&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24678">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24678.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The incidence of primary cutaneous melanoma has increased steadily for several decades and remains the most lethal form of cutaneous neoplasm. If diagnosed in the early stages, melanoma has high survival rates, approximating 94%.<xref ref-type="bibr" rid="article-24678.r1">[1]</xref> According to the National Cancer Institute (NCI), from 2014 to 2018, the incidence of metastatic melanoma was estimated to be 0.9 per 100,000.&#x000a0;Mucosal and ocular melanomas typically have worse prognoses.<xref ref-type="bibr" rid="article-24678.r2">[2]</xref>&#x000a0;Melanoma was once considered&#x000a0;a very&#x000a0;aggressive cancer that was resistant to traditional therapies such as chemotherapy, radiation, and even single-agent targeted therapies in their early stages of development. A dramatic improvement in the quality of life and overall survival of patients with metastatic melanoma has resulted after the advent of various new combinations of targeted therapies and different modalities of immunotherapies.&#x000a0;</p>
        <p>Melanoma is distinct from nonmelanoma skin cancers because it spreads locally, regionally, and distantly. An individual's risk of metastasis is directly related to the depth of invasion and ulceration of the primary lesion. The early stages of cancer metastasis involve invasion, angiogenesis, extravasation, dissemination, and colonization of the target organ. Patients with clinically node-negative disease and those with negative sentinel lymph node biopsy can still present with distant metastatic disease. Moreover, complete lymph node dissection has not been proven to offer a survival benefit to patients with node-positive disease.<xref ref-type="bibr" rid="article-24678.r3">[3]</xref>&#x000a0;There are reports of the transfer of melanoma from a donor to a recipient after an organ transplant, even when the transplant was performed years after the donor was diagnosed with melanoma.<xref ref-type="bibr" rid="article-24678.r4">[4]</xref>&#x000a0;Such distant seeding suggests the possibility of early subclinical micrometastasis in melanoma. According to the American Society of Clinical Oncology (ASCO), only about 4% of melanomas are present with metastasis.&#x000a0;</p>
        <p>Patients typically present with an asymmetrical large lesion that&#x000a0;may also itch, bleed, ulcerate, or develop satellite lesions. Patients who present with metastatic disease or with primary sites other than the skin have signs and symptoms related to the affected organ systems. Once a suspicious skin lesion is identified, a biopsy must be performed to confirm the diagnosis of melanoma. An excisional biopsy is the preferred biopsy modality. Melanoma treatment typically involves wide local excision, Mohs micrographic surgery, digital amputations, or adjuvant therapy depending on tumor location, depth, ulceration, lymph node involvement, and metastasis.&#x000a0;</p>
      </sec>
      <sec id="article-24678.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Multiple causes have been postulated in the development of malignant melanoma, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Family history</bold>: A positive family history is noted in 5%&#x000a0;to 10% of patients with melanoma. There is a 2.2-fold higher risk of developing melanoma with at least 1 affected family member.</p>
          </list-item>
          <list-item>
            <p><bold>Personal characteristics</bold>: Blue eyes, fair or red hair, pale complexion, history of sunburns, freckled skin, history of benign or dysplastic melanocytic nevi with the number of lesions showing a stronger correlation than size, and immunocompromised state (eg, posttransplant patients, patients with hematologic malignancies) are known high-risk factors.</p>
          </list-item>
          <list-item>
            <p><bold>Lifetime sun exposure</bold>:&#x000a0;High UVB and UVA radiation exposure. Recent evidence has shown that the risk of melanoma is higher in people who use sunscreen. This is because sunscreen primarily blocks UVB, and therefore, people using sunscreen may be exposed to UVA more than the general public, provided those people are exposed to the sun more than the public at large. Risks of melanoma increase with decreasing or increasing latitude.<xref ref-type="bibr" rid="article-24678.r5">[5]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Atypical mole syndrome</bold>: Formerly termed B-K mole syndrome, dysplastic nevus syndrome, or familial atypical multiple mole (FAMM) syndrome. Over 10 years, patients with atypical mole syndrome have a 10.7% risk of melanoma versus 0.62% of controls. There is a higher risk of melanoma depending on the number of family members affected, with nearly 100% risk if&#x000a0;&#x02265;2 relatives have dysplastic nevi and melanoma.</p>
          </list-item>
          <list-item>
            <p>
<bold>Tanning bed use</bold>
</p>
          </list-item>
          <list-item>
            <p><bold>Socioeconomic status</bold>: Lower socioeconomic status may be linked to more advanced disease at the time of detection. Several studies of newly diagnosed patients found that patients&#x000a0;of low socioeconomic status have decreased melanoma risk perception, knowledge of the disease, and preventative practices.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24678.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>According to the NCI's Surveillance, Epidemiology, and End Results (SEER) program, melanoma is currently the fifth most common malignancy in both men and women. Experts estimate that in 2023, 97,610 new cases of melanoma will be diagnosed in the US, with an estimated 7,990 deaths associated with melanoma.<xref ref-type="bibr" rid="article-24678.r1">[1]</xref></p>
        <p>Melanoma is caused by several factors, including environmental, genetic, and immunological.<xref ref-type="bibr" rid="article-24678.r6">[6]</xref><xref ref-type="bibr" rid="article-24678.r7">[7]</xref><xref ref-type="bibr" rid="article-24678.r8">[8]</xref> In particular, melanoma research has focused on activating the immune system and understanding various cancer signal transduction pathways,&#x000a0;with the successful development of effective immunotherapies&#x000a0;and targeted therapies, respectively.&#x000a0;The genes associated with melanoma predisposition are&#x000a0;<italic toggle="yes">CDKN2A, CDK4, MC1R. </italic>The genetic disorder xeroderma pigmentosum (XP) is also associated with melanoma and results in the improper repair of ultraviolet (UV)-induced DNA damage and, therefore, a high mutation rate.<xref ref-type="bibr" rid="article-24678.r9">[9]</xref><xref ref-type="bibr" rid="article-24678.r10">[10]</xref><xref ref-type="bibr" rid="article-24678.r11">[11]</xref><xref ref-type="bibr" rid="article-24678.r12">[12]</xref></p>
      </sec>
      <sec id="article-24678.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Melanoma&#x000a0;has a relatively high risk of systemic spread. Melanoma has several well-defined clinical attributes and risk factors. Molecular studies, genetics, and next-generation sequencing have revealed that the <italic toggle="yes">BRAF V600E</italic> mutation plays a crucial role in oncogenesis. These studies have also demonstrated that UV-induced DNA mutations play a significant role in melanoma development and carry a high mutation burden. Immunotherapy and targeted therapies have significantly improved the&#x000a0;survival rates and outcomes associated with metastatic melanoma. Despite this, several challenges remain in understanding the biology&#x000a0;of therapeutic resistance and relapses.&#x000a0;</p>
        <p>Melanocytes are neural crest-derived cells in the basal layer of the epidermis and located in the skin, hair, uvea mucosal epithelia, and meninges. The primary function of melanocytes is to synthesize melanin within melanosomes and transfer melanin via dendritic processes to neighboring keratinocytes. Melanocytes produce 2 forms of melanin pigment, eumelanin and pheomelanin, derived from precursor tyrosinase.<xref ref-type="bibr" rid="article-24678.r13">[13]</xref></p>
        <p>Many factors can promote melanoma development, including exposure to UV rays.<xref ref-type="bibr" rid="article-24678.r14">[14]</xref><xref ref-type="bibr" rid="article-24678.r15">[15]</xref><xref ref-type="bibr" rid="article-24678.r16">[16]</xref>&#x000a0;<xref ref-type="bibr" rid="article-24678.r17">[17]</xref>&#x000a0;People of the same ethnicity experience different rates of melanoma depending on their geographical location. Locations differ in terms of atmospheric absorption, latitude, altitude, cloud cover, levels of ozone layer depletion, and seasonality, thus impacting incident UV radiation.<xref ref-type="bibr" rid="article-24678.r18">[18]</xref>&#x000a0;Genetic factors also influence the pathogenesis of melanoma. The BRAF mutation was detected in patients with melanoma without chronic sun damage in 2005 by Uhara et al.<xref ref-type="bibr" rid="article-24678.r19">[19]</xref><xref ref-type="bibr" rid="article-24678.r20">[20]</xref>&#x000a0;Several studies have shown that nearly 40% to 50% of cutaneous melanomas have mutations in <italic toggle="yes">BRAF</italic>, a serine/threonine-protein kinase associated with the RAS-RAF-MEK pathway.<xref ref-type="bibr" rid="article-24678.r21">[21]</xref>&#x000a0;The <italic toggle="yes">BRAF</italic> mutation activates the mitogen-activated protein (MAP) kinase pathway, which starts at the cell surface and signals through RAS, then RAF, followed by mitogen-activated protein kinase (MEK) and extracellular signal-regulated kinase (ERK). ERK is the final protein in this cascade, which affects the expression of genes within the nucleus and leads to cell proliferation.&#x000a0;The most common mutation is the V600E, although a different mutation called V600K has also been found in some cases.</p>
        <p>Certain types of melanoma are associated with cumulative solar damage (CSD). However, in some cases, the etiology is not always clear.<xref ref-type="bibr" rid="article-24678.r22">[22]</xref>&#x000a0;The 2018 World Health Organization (WHO) Classification of Melanoma&#x000a0;categorizes melanomas into the following categories:<xref ref-type="bibr" rid="article-24678.r22">[22]</xref></p>
        <p>
<bold>Melanomas Typically Associated with Cumulative Solar Damage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pathway I. Superficial spreading melanoma/low-CSD melanoma</p>
          </list-item>
          <list-item>
            <p>Pathway II. Lentigo maligna melanoma/high-CSD melano a</p>
          </list-item>
          <list-item>
            <p>Pathway III. Desmoplastic melanoma</p>
          </list-item>
        </list>
        <p>
<bold>Melanomas Not Consistently Associated with&#x000a0;Cumulative Solar Damage</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pathway IV. Spitz melanomas</p>
          </list-item>
          <list-item>
            <p>Pathway V. Acral melanoma</p>
          </list-item>
          <list-item>
            <p>Pathway VI. Mucosal melanomas</p>
          </list-item>
          <list-item>
            <p>Pathway VII. Melanomas arising in congenital nevi</p>
          </list-item>
          <list-item>
            <p>Pathway VIII. Melanomas arising in blue nevi</p>
          </list-item>
          <list-item>
            <p>Pathway IX. Uveal melanoma</p>
          </list-item>
        </list>
        <p>
<bold>Nodular Melanomas&#x000a0;</bold>
</p>
        <p>Nodular melanoma may occur in any or most of the pathways. Four major variants of primary cutaneous melanoma are:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Superficial spreading melanoma</bold>
<list list-type="bullet"><list-item><p>Most common type of melanoma&#x000a0;</p></list-item><list-item><p>Exhibition of hallmark melanoma features: asymmetry, irregular borders, color, and increased diameter&#x000a0;<xref ref-type="bibr" rid="article-24678.r23">[23]</xref></p></list-item><list-item><p>Prolonged radial growth phase, characterized by intraepidermal expansion&#x000a0;</p></list-item><list-item><p>No dermal invasion&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Nodular melanoma</bold>&#x000a0;
<list list-type="bullet"><list-item><p>Located in chronically sun-exposed areas, the head and neck.&#x000a0;</p></list-item><list-item><p>Histologically, a vertical growth phase only and an absent radial growth phase</p></list-item><list-item><p>Rapid growth and usually presents at an advanced Breslow depth&#x000a0;</p></list-item><list-item><p>15% to 20% of primary melanomas and responsible for 40% of melanoma deaths&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Lentigo maligna melanoma</bold>&#x000a0;
<list list-type="bullet"><list-item><p>Elderly patients with chronically sun-damaged skin on the face&#x000a0;</p></list-item><list-item><p>Initiation&#x000a0;from an in situ lentigo maligna precursor that presents as a slowly enlarging and evolving brown-to-black macule with irregular borders&#x000a0;</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Acral lentiginous melanoma</bold>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24678.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The primary types of malignant melanoma seen on histologic examination include superficial spreading, nodular, lentigo, and acral lentiginous melanomas (see <bold>Image.</bold> Malignant Melanoma).</p>
        <p>
<bold>Superficial Spreading Melanomas</bold>
</p>
        <p>Epidermal findings commonly seen in superficial spreading melanomas include unrestricted melanocytes, an increased number of singular melanocytes rather than melanocyte nests, abnormally distributed and&#x000a0;nonconjoined melanocytes, and melanocytes identified above the basal layer (ie, Pagetoid spread).<xref ref-type="bibr" rid="article-24678.r24">[24]</xref>&#x000a0;See&#x000a0;<bold>Image.</bold>&#x000a0;Superficial&#x000a0;Melanoma.</p>
        <p>
<bold>Nodular Melanomas</bold>
</p>
        <p>Nodular melanomas have similar findings to superficial spreading melanomas, except that nodular melanomas are sharply circumscribed. Instead, the epidermal component mirrors the dermal component and does not extend beyond the dermal borders. However, these neoplasms have a poor prognosis because they have a higher rate of growth and metastasis (see&#x000a0;<bold>Image.</bold>&#x000a0;Nodular&#x000a0;Melanoma).<xref ref-type="bibr" rid="article-24678.r24">[24]</xref>&#x000a0;</p>
        <p>
<bold>Lentigo Maligna Melanomas</bold>
</p>
        <p>Characteristic histologic findings of these lesions include epidermal atrophy secondary to severe sun damage and melanocytes running together along the dermal-epidermal junction with epithelial extension. Small, hyperchromatic cells with dense nuclear chromatin are typical. However, cell nucleoli are usually not seen. Multinucleated melanoma cells are also common. Pagetoid spread is usually only seen with advanced disease.<xref ref-type="bibr" rid="article-24678.r24">[24]</xref></p>
        <p>
<bold>Acral Lentiginous Melanomas</bold>
</p>
        <p>This type of melanoma is rare, usually found in nailbeds, and therefore has a delayed diagnosis. Histologic findings associated with acral lentiginous melanoma include melanocytes in nests and as isolated cells along the dermal junction.&#x000a0;Widespread pagetoid spread upwards is typical. Pagetoid spread can also be observed in benign forms of this tumor but usually has minimal extension. Melanocytes are often hyperchromatic, and nucleoli are challenging to visualize.<xref ref-type="bibr" rid="article-24678.r24">[24]</xref></p>
      </sec>
      <sec id="article-24678.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The characteristic signs of early melanoma are recognized with the following well-known ABCDE mnemonic:</p>
        <list list-type="bullet">
          <list-item>
            <p>&#x0201c;<bold>A</bold>&#x0201d; stands for&#x000a0;<bold>A</bold>symmetry</p>
          </list-item>
          <list-item>
            <p>&#x0201c;<bold>B</bold>&#x0201d; stands for&#x000a0;<bold>B</bold>order: irregular, ragged, notched, or blurred edges</p>
          </list-item>
          <list-item>
            <p>&#x0201c;<bold>C</bold>&#x0201d; stands for&#x000a0;<bold>C</bold>olor: nonuniform or variegated</p>
          </list-item>
          <list-item>
            <p>&#x0201c;<bold>D</bold>&#x0201d; stands for&#x000a0;<bold>D</bold>iameter: larger than 6 millimeters</p>
          </list-item>
          <list-item>
            <p>&#x0201c;<bold>E</bold>&#x0201d; stands for&#x000a0;<bold>E</bold>volving<bold>:</bold>&#x000a0;changes in size, shape, or color&#x000a0;<xref ref-type="bibr" rid="article-24678.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>See <bold>Image.</bold>&#x000a0;Melanoma. Dermoscopy can also be&#x000a0;an important tool in distinguishing benign or malignant lesions.<xref ref-type="bibr" rid="article-24678.r26">[26]</xref><xref ref-type="bibr" rid="article-24678.r27">[27]</xref>&#x000a0;Once diagnosed, melanoma is staged using American Joint Committee on Cancer (AJCC) guidelines, which guide treatment and determine prognosis.<xref ref-type="bibr" rid="article-24678.r28">[28]</xref>&#x000a0;Also, melanomas may itch, bleed, ulcerate, or develop satellite lesions. Patients who present with metastatic disease or with primary sites other than the skin have signs and symptoms related to the affected organ systems. Examining all lymph node groups as part of the evaluation is also important.</p>
      </sec>
      <sec id="article-24678.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A whole-body skin examination is the most essential and fundamental evaluation needed in diagnosing melanoma, and it should be performed in the presence of optimal lighting. Skin examination is often complemented with a dermatoscopy of suspicious lesions. Using this evaluation, the assessment of "ABCDE" is completed. During this examination, attention must be paid to examining nail units. This is important for properly diagnosing abnormal melanomas, which follow a slightly different mnemonic ABCDEF, where the "F" stands for family or personal history of melanoma.&#x000a0;</p>
        <p>Once a suspicious skin lesion is identified, a biopsy must be performed to confirm the diagnosis of melanoma. An excisional biopsy is the preferred modality of biopsy. However, an incisional biopsy might be acceptable in certain situations, especially for subungual lesions, lesions on palms or soles, or large lesions.<xref ref-type="bibr" rid="article-24678.r29">[29]</xref><xref ref-type="bibr" rid="article-24678.r30">[30]</xref><xref ref-type="bibr" rid="article-24678.r31">[31]</xref>&#x000a0;Obtaining a complete or excisional biopsy is preferred since the tumor staging of melanoma is based on the depth of invasion.&#x000a0;(see&#x000a0;<bold>Image.</bold>&#x000a0;Dermal Invasion by Melanoma). These results will further confirm the staging and necessitate additional investigations, including sentinel lymph node evaluation or the need for staging workup with imaging studies.&#x000a0;</p>
        <p>The following laboratory studies are indicated:</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count</p>
          </list-item>
          <list-item>
            <p>Complete chemistry panel including alkaline phosphatase, hepatic transaminases, total protein, and albumin</p>
          </list-item>
          <list-item>
            <p>Lactate dehydrogenase</p>
          </list-item>
        </list>
        <p>The following imaging modalities may be considered:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chest radiography</p>
          </list-item>
          <list-item>
            <p>Magnetic resonance imaging (MRI) of the brain</p>
          </list-item>
          <list-item>
            <p>Ultrasonography, possibly the best imaging study for diagnosing lymph node involvement</p>
          </list-item>
          <list-item>
            <p>computed tomography (CT) of the chest, abdomen, or pelvis</p>
          </list-item>
          <list-item>
            <p>Positron emission tomography (PET), PET-CT may be the best imaging study for identifying any sites of metastasis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24678.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Melanomas diagnosed in earlier stages are treated primarily with surgical intervention involving excision of the tumor using a wide local excision technique if excisional biopsy results in positive or close margins. In addition, sentinel lymph node biopsy and wide local excision for any tumor T1b or higher are completed. In cases where primary closure is impossible due to large-sized lesions, skin grafting or tissue transfer techniques are needed as part of the reconstruction.<xref ref-type="bibr" rid="article-24678.r32">[32]</xref><xref ref-type="bibr" rid="article-24678.r33">[33]</xref><xref ref-type="bibr" rid="article-24678.r34">[34]</xref><xref ref-type="bibr" rid="article-24678.r35">[35]</xref>&#x000a0;Typically, wide local excision is performed up to the muscle fascia. The following are the optimal margins for wide excision currently derived from various large clinical trials and can be summarized below:<xref ref-type="bibr" rid="article-24678.r36">[36]</xref><xref ref-type="bibr" rid="article-24678.r37">[37]</xref><xref ref-type="bibr" rid="article-24678.r38">[38]</xref><xref ref-type="bibr" rid="article-24678.r39">[39]</xref><xref ref-type="bibr" rid="article-24678.r40">[40]</xref><xref ref-type="bibr" rid="article-24678.r41">[41]</xref><xref ref-type="bibr" rid="article-24678.r42">[42]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Melanoma in situ (Tis): 0.5 to 1 cm</p>
          </list-item>
          <list-item>
            <p>T1 (&#x02264;1 mm): 1 cm</p>
          </list-item>
          <list-item>
            <p>T2 (&#x02265;1 to 2 mm): 1 to 2 cm</p>
          </list-item>
          <list-item>
            <p>T3 or T4 (&#x0003e;2 mm): 2 cm</p>
          </list-item>
        </list>
        <p>For melanoma in situ, Mohs micrographic surgery may be an option, aside from wide local excision. For melanomas arising in unusual sites, like subungual melanomas, digital amputations are recommended. However, for melanoma in situ in subungual areas, there could be an option for digit-preserving surgeries. Various high-risk features could be noted on the final pathology specimen after wide excision and sentinel lymph node biopsy, including tumor depth, ulceration, and lymph node involvement that would determine the need for adjuvant therapies.<xref ref-type="bibr" rid="article-24678.r43">[43]</xref>&#x000a0;</p>
        <p>Sentinel lymph node biopsy is recommended in patients with melanomas where there is an increased risk of regional node metastasis. This is determined primarily by the depth of melanoma or Breslow's depth and is recommended in melanomas with T1b or higher staging.<xref ref-type="bibr" rid="article-24678.r44">[44]</xref><xref ref-type="bibr" rid="article-24678.r45">[45]</xref>&#x000a0;If lymph node involvement is noted on sentinel lymph node evaluation, the current preference, as per national oncology societies, is observation rather than completion of lymph node dissection. This is based on the results from a phase III Multicenter Selective Lymphadenectomy Trial II (MSLT-II), which demonstrated no difference in melanoma-specific survival between&#x000a0;these 2 groups.<xref ref-type="bibr" rid="article-24678.r3">[3]</xref>&#x000a0;However, there was an improvement in the lymphadenectomy group compared to the observation group regarding 3-year disease-free survival or recurrence in regional lymph nodes, at the expense of higher incidences of lymphedema.&#x000a0;</p>
        <p>
<bold>Adjuvant Therapies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage IB (T2a) or stage II (&#x02265;T2b)
<list list-type="bullet"><list-item><p>If sentinel lymph node biopsy returns negative, patients can either be observed or enrolled in clinical trials or receive 1 year of adjuvant pembrolizumab for stages IIB and IIC.<xref ref-type="bibr" rid="article-24678.r46">[46]</xref><xref ref-type="bibr" rid="article-24678.r47">[47]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stage IIIA (sentinel node-positive) with low-risk disease
<list list-type="bullet"><list-item><p>Low-risk disease includes tumors &#x02264;2 mm in thickness, and sentinel node contains &#x0003c;1 mm tumor.</p></list-item><list-item><p>Given the low risk of disease recurrence, these patients can be safely observed or receive 1 year of adjuvant nivolumab, pembrolizumab, or dabrafenib/trametinib if <italic toggle="yes">BRAF</italic> mutated.<xref ref-type="bibr" rid="article-24678.r48">[48]</xref><xref ref-type="bibr" rid="article-24678.r28">[28]</xref><xref ref-type="bibr" rid="article-24678.r49">[49]</xref><xref ref-type="bibr" rid="article-24678.r50">[50]</xref><xref ref-type="bibr" rid="article-24678.r51">[51]</xref><xref ref-type="bibr" rid="article-24678.r52">[52]</xref><xref ref-type="bibr" rid="article-24678.r51">[51]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stage IIIA/B/C/D (sentinel node-positive)
<list list-type="bullet"><list-item><p>Adjuvant systemic therapy options include nivolumab,&#x000a0;pembrolizumab,&#x000a0;or dabrafenib/trametinib if <italic toggle="yes">BRAF</italic>&#x000a0;mutated.<xref ref-type="bibr" rid="article-24678.r51">[51]</xref><xref ref-type="bibr" rid="article-24678.r50">[50]</xref><xref ref-type="bibr" rid="article-24678.r52">[52]</xref><xref ref-type="bibr" rid="article-24678.r50">[50]</xref><xref ref-type="bibr" rid="article-24678.r51">[51]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stage III (clinically node-positive)
<list list-type="bullet"><list-item><p>If the patient has resectable nodal disease, then after completing wide local excision and therapeutic lymph node dissection, the patient should be offered nivolumab or pembrolizumab or dabrafenib/trametinib if <italic toggle="yes">BRAF</italic>&#x000a0;mutated. In addition, the patient could be considered for radiation therapy to the lymph node basin depending on the location, size, and number of lymph nodes involved.<xref ref-type="bibr" rid="article-24678.r53">[53]</xref><xref ref-type="bibr" rid="article-24678.r54">[54]</xref></p></list-item><list-item><p>If the patient has borderline resectable disease, then patients could have the option of receiving neoadjuvant therapies, raising either single-agent pembrolizumab<xref ref-type="bibr" rid="article-24678.r55">[55]</xref> or the combination of ipilimumab and nivolumab.<xref ref-type="bibr" rid="article-24678.r56">[56]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>In current clinical practice, interferon alfa is rarely used in adjuvant settings.</p>
      </sec>
      <sec id="article-24678.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses of malignant melanoma include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Atypical fibroxanthoma</p>
          </list-item>
          <list-item>
            <p>Pigmented basal cell carcinoma</p>
          </list-item>
          <list-item>
            <p>Blue nevus</p>
          </list-item>
          <list-item>
            <p>Epithelioid tumor</p>
          </list-item>
          <list-item>
            <p>Halo nevus</p>
          </list-item>
          <list-item>
            <p>Histiocytoid hemangioma</p>
          </list-item>
          <list-item>
            <p>Mycosis fungoides</p>
          </list-item>
          <list-item>
            <p>Pigmented spindle cell tumor</p>
          </list-item>
          <list-item>
            <p>Sebaceous carcinoma</p>
          </list-item>
          <list-item>
            <p>Dermatofibroma</p>
          </list-item>
          <list-item>
            <p>Seborrheic keratosis</p>
          </list-item>
          <list-item>
            <p>Cherry hemangioma</p>
          </list-item>
          <list-item>
            <p>Lentigo</p>
          </list-item>
          <list-item>
            <p>Subungual hematoma</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24678.s11" sec-type="Staging">
        <title>Staging</title>
        <p>Cutaneous melanoma staging is based on the American Joint Committee on Cancer (AJCC) 8th edition tumor, node, and metastasis (TNM) staging system guidelines.&#x000a0;Tumor staging depends on tumor thickness and ulceration status. Nodal involvement and extent of metastatic spread define nodal and metastasis staging, respectively.&#x000a0;</p>
        <p>
<bold>Tumor</bold>
</p>
        <p>TX: Primary tumor thickness cannot be assessed (eg, diagnosis by curettage)&#x000a0;</p>
        <p>T0: No evidence of primary tumor (eg, unknown primary or completely regressed melanoma)&#x000a0;</p>
        <p>Tis (ie, melanoma in situ)&#x000a0;</p>
        <p>T1: &#x02264;1 mm&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>T1a: &#x0003c;0.8 mm without ulceration</p>
          </list-item>
          <list-item>
            <p>T1b: &#x0003c;0.8 mm with ulceration</p>
          </list-item>
        </list>
        <p>T2: &#x0003c;1 to 2 mm</p>
        <list list-type="bullet">
          <list-item>
            <p>T2a:&#x000a0;&#x0003c;1 to 2 mm without ulceration</p>
          </list-item>
          <list-item>
            <p>T2b:&#x000a0;&#x0003c;1 to 2 mm with ulceration</p>
          </list-item>
        </list>
        <p>T3: &#x0003e;2 to 4 mm</p>
        <list list-type="bullet">
          <list-item>
            <p>T3a:&#x000a0;&#x0003e;2 to 4 mm without ulceration</p>
          </list-item>
          <list-item>
            <p>T3b:&#x000a0;&#x0003e;2 to 4 mm with ulceration</p>
          </list-item>
        </list>
        <p>T4: &#x0003e;4.0 mm</p>
        <list list-type="bullet">
          <list-item>
            <p>T4a:&#x000a0;&#x0003e;4.0 mm without ulceration</p>
          </list-item>
          <list-item>
            <p>T4b:&#x000a0;&#x0003e;4.0 mm with ulceration</p>
          </list-item>
        </list>
        <p>
<bold>Node</bold>
</p>
        <p>NX: Regional nodes not assessed</p>
        <p>N0: No regional metastases detected</p>
        <p>N1: 1 tumor-involved node or in-transit, satellite, or microsatellite metastases with no tumor-involved nodes</p>
        <list list-type="bullet">
          <list-item>
            <p>N1a: 1 clinically occult (ie, detected by SLN biopsy)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>N1b: 1 clinically detected</p>
          </list-item>
          <list-item>
            <p>N1c:&#x000a0;No regional lymph node disease but with&#x000a0;the presence of in-transit or satellite or microsatellite metastases</p>
          </list-item>
        </list>
        <p>N2: 2 to 3 tumor-involved nodes or in-transit, satellite, and microsatellite metastases with 1 tumor-involved node</p>
        <list list-type="bullet">
          <list-item>
            <p>N2a: 2 to 3 clinically occult (ie, detected by SLN biopsy)</p>
          </list-item>
          <list-item>
            <p>N2b: 2 to 3, at least 1&#x000a0; clinically detected</p>
          </list-item>
          <list-item>
            <p>N2c: 1 clinically occult or clinically detected with the presence of in-transit or satellite or microsatellite metastases</p>
          </list-item>
        </list>
        <p>N3:&#x000a0;&#x02265;4 tumor-involved nodes or in-transit, satellite, or microsatellite metastases with &#x02265;2 tumor-involved nodes or any matted nodes without or with in-transit, satellite, or microsatellite metastases</p>
        <list list-type="bullet">
          <list-item>
            <p>N3a:&#x000a0;&#x02265;4 clinically occult (ie, detected by SLN biopsy)</p>
          </list-item>
          <list-item>
            <p>N3b:&#x000a0;&#x02265;4, at least 1 of which was clinically detected, or the presence of any number of matted nodes</p>
          </list-item>
          <list-item>
            <p>N3c:&#x000a0;&#x02265;2 clinically occult or clinically detected or the presence of any matted nodes with&#x000a0;the presence of in-transit or satellite or microsatellite metastases</p>
          </list-item>
        </list>
        <p>
<bold>Metastasis</bold>
</p>
        <p>M0:&#x000a0;No evidence of distant metastasis</p>
        <p>M1:&#x000a0;Evidence of distant metastasis</p>
        <list list-type="bullet">
          <list-item>
            <p>M1a(0): Distant metastasis to the skin, soft tissue including muscle, or nonregional lymph node</p>
          </list-item>
          <list-item>
            <p>M1a(1): Distant metastasis to the skin, soft tissue including muscle, or nonregional lymph node with elevated LDH</p>
          </list-item>
          <list-item>
            <p>M1b(0): Distant metastasis to the lung with or without M1a sites of disease</p>
          </list-item>
          <list-item>
            <p>M1b(1):&#x000a0;Distant metastasis to the lung with or without M1a sites of disease with elevated LDH</p>
          </list-item>
          <list-item>
            <p>M1c(0):&#x000a0;Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease</p>
          </list-item>
          <list-item>
            <p>M1c(1): Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease with elevated LDH</p>
          </list-item>
          <list-item>
            <p>M1d(0):&#x000a0;Distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease</p>
          </list-item>
          <list-item>
            <p>M1d(1):&#x000a0;Distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease with elevated LDH</p>
          </list-item>
        </list>
        <table-wrap id="article-24678.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. TNM Staging Summary</title>
          </caption>
          <table style="margin-left: auto; margin-right: auto; width: 800px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;<bold>Stage</bold></td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">
<bold>T</bold>
</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">
<bold>N</bold>
</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">
<bold>M</bold>
</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>0</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">Tis</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IA</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T1a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IB</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T1b</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T2a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IIA</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T2b</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T3a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IIB</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T3b</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T4a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IIC</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T4b</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N0</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IIIA</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T1a/b, T2a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N1a, N2a</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IIIB</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T0</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N1b, N1c</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T1a/b, T2a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">T1a/b, T2a</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T2b, T3a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N1a/b/c, N2a/b</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IIIC</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T0</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N2b/c, N3b/c</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T1a/b, T2a/b, T3a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N2c, N3a/b/c</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T3b, T4a</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">Any N &#x02265; N1</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T4b</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N1a/b/c, N2a/b/c</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IIID</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">T4b</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">N3a/b/c</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M0</td>
              </tr>
              <tr>
                <td style="width: 203.219px; text-align: center;" rowspan="1" colspan="1">
<bold>IV</bold>
</td>
                <td style="width: 235.781px; text-align: center;" rowspan="1" colspan="1">Any T, Tis</td>
                <td style="width: 211px; text-align: center;" rowspan="1" colspan="1">Any N</td>
                <td style="width: 187px; text-align: center;" rowspan="1" colspan="1">M1</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-24678.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Poor prognostic factors that affect survival in melanoma include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tumor thickness, with a worse prognosis in thicker lesions</p>
          </list-item>
          <list-item>
            <p>Evidence of tumor in regional lymph nodes (ie, stage III disease)</p>
          </list-item>
          <list-item>
            <p>A higher number of positive lymph nodes</p>
          </list-item>
          <list-item>
            <p>Presence of distant metastasis (ie, stage IV disease)</p>
          </list-item>
          <list-item>
            <p>Anatomic site, with trunk or face lesions having a worse prognosis than extremity lesions</p>
          </list-item>
          <list-item>
            <p>Presence of ulceration</p>
          </list-item>
          <list-item>
            <p>Presence of regression on histologic examination, though this is controversial</p>
          </list-item>
          <list-item>
            <p>Male sex</p>
          </list-item>
        </list>
        <p>The following are the reported survival rates depending on the disease stage at diagnosis:<xref ref-type="bibr" rid="article-24678.r28">[28]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 0: 5-year overall survival rate of 99% to 100%</p>
          </list-item>
          <list-item>
            <p>Stage IA: 5-year overall survival rate of&#x000a0;99%</p>
          </list-item>
          <list-item>
            <p>Stage IB: 5-year overall survival rate of&#x000a0;97%</p>
          </list-item>
          <list-item>
            <p>Stage IIA:&#x000a0;5-year overall survival rate of 94%</p>
          </list-item>
          <list-item>
            <p>Stage IIB:&#x000a0;5-year overall survival rate of 87%</p>
          </list-item>
          <list-item>
            <p>Stage IIC:&#x000a0;5-year overall survival rate of 82%</p>
          </list-item>
          <list-item>
            <p>Stage IIIA:&#x000a0;5-year overall survival rate of 93%</p>
          </list-item>
          <list-item>
            <p>Stage IIIB:&#x000a0;5-year overall survival rate of 83%</p>
          </list-item>
          <list-item>
            <p>Stage IIIC:&#x000a0;5-year overall survival rate of 69%</p>
          </list-item>
          <list-item>
            <p>Stage IIID:&#x000a0;5-year overall survival rate of 32%</p>
          </list-item>
          <list-item>
            <p>Stage IV:&#x000a0;5-year overall survival rate of 34% to 52%&#x000a0;<xref ref-type="bibr" rid="article-24678.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24678.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Management of malignant melanoma involves a combination of surgery, radiation therapy in very few cases, adjuvant immunotherapy, or targeted therapies. These interventions, which are proven to improve survival and long-term outcomes associated with melanoma, are associated with some potential complications.&#x000a0;</p>
        <p>Surgery can be associated with complications, including bleeding, infection, damage to nerves, and scarring. Cosmetic outcomes from surgery might also have psychological implications, including depression and anxiety. In patients undergoing lymph node dissection, there is an increased incidence of lymphedema.&#x000a0;In a few patients who receive radiation to the lymph node basin for extensive lymph node involvement, there could be potential radiotherapy-related complications, including skin irritation, fatigue, risk of secondary malignancies, and lymphedema.&#x000a0;</p>
        <p>Adjuvant therapies, including immunotherapies and targeted therapies, have various potential adverse effects that could complicate the treatment course. These include immunotherapy-related adverse events (irAEs) and targeted therapy-related&#x000a0;drug-induced fevers, risk of secondary malignancies, fatigue, risk of infections, and immunosuppression.</p>
        <p>All these potential complications can affect the quality of life of a patient, along with the inability to complete the treatment course, which could result in an increased risk of recurrence and&#x000a0;poorer survival outcomes. Therefore, vigilance is essential due to the potential complications of various management strategies. Additionally, selecting the appropriate therapy and monitoring patients is critical.</p>
      </sec>
      <sec id="article-24678.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated and counseled to practice important&#x000a0;primary as well as secondary preventative strategies, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sun protection measures (eg, wearing protective clothing and using sunscreen with appropriate SPF strength)</p>
          </list-item>
          <list-item>
            <p>Avoiding mid-day sun exposure</p>
          </list-item>
          <list-item>
            <p>Avoiding tanning beds</p>
          </list-item>
          <list-item>
            <p>Annual dermatology evaluations</p>
          </list-item>
          <list-item>
            <p>Regular skin checks with immediate assessment of any spot changes</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24678.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Primary care clinicians, dermatologists, surgeons, medical oncologists, and radiation oncologists frequently detect and manage melanoma, so an interprofessional/multidisciplinary team approach is needed. While many skin lesions are benign, clinicians should always consider melanoma a potentially deadly diagnosis to miss. If there is suspicion of melanoma, the patient should obtain a referral to the dermatologist for further workup, irrespective of which other healthcare clinicians first became suspicious. Surgery includes wide local excision with sentinel lymph node biopsy,&#x000a0;followed by lymph node dissection in some cases. These surgical procedures are the definitive treatment for early-stage melanoma.</p>
        <p>The surgical margins are the most critical consideration when performing the wide local excision. If the primary closure is not feasible, skin grafting or tissue transfers may be needed.&#x000a0;Medical management is reserved for adjuvant therapy of patients with higher-stage melanoma. Dermatologists continue to be involved in the care of patients with melanoma indefinitely, sometimes even in the presence of metastatic disease.&#x000a0;For localized lesions, the prognosis is with surgery. Still, advanced melanoma has a&#x000a0;grim prognosis, but the interprofessional team approach to care will optimize the patient's prospects for a better outcome.</p>
      </sec>
      <sec id="article-24678.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24678&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24678">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/malignant-melanoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24678">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24678/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24678">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24678.s17">
        <fig id="article-24678.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Melanoma <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="superficial__melanoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24678.s18">
        <fig id="article-24678.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Malignant Melanoma Contributed by S Jones, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Malignant_melanoma_x1x_at_thigh_Case_01" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24678.s19">
        <fig id="article-24678.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Superficial Melanoma. Histopathology shows an atypical proliferation of melanocytes in the dermis, in a diffuse pattern. The architecture is altered by epidermal invasion and erosion. H/E 4x Contributed by Fabiola Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="758-2011" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24678.s20">
        <fig id="article-24678.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Nodular Melanoma. Nodular melanoma with vertical growth phase and deep dermal invasion. H/E 4x Contributed by Fabiola Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_20200320_084626" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24678.s21">
        <fig id="article-24678.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Dermal Invasion by Melanoma. Malignant melanocytic proliferation enhanced by MART1 / MELAN-A immunohistochemical stain with deep dermal invasion. 4x Contributed by Fabiola Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_20200320_090545" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24678.s22">
        <title>References</title>
        <ref id="article-24678.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Wagle</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer statistics, 2023.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-48</page-range>
            <pub-id pub-id-type="pmid">36633525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Lubner</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Menias</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Mellnick</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bhalla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pickhardt</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Imaging Features of Noncutaneous Melanoma.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2017</year>
            <month>May</month>
            <volume>208</volume>
            <issue>5</issue>
            <fpage>942</fpage>
            <page-range>942-959</page-range>
            <pub-id pub-id-type="pmid">28301211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faries</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Cochran</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Andtbacka</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Mozzillo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zager</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Jahkola</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bowles</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Testori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beitsch</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Moncrieff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ingvar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wouters</surname>
                <given-names>MWJM</given-names>
              </name>
              <name>
                <surname>Sabel</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Agnese</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Neves</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Trocha</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Matter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hsueh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>MacKenzie-Ross</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Terheyden</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Huston</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Wayne</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smithers</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Neuman</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Schneebaum</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Ariyan</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McMasters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gesierich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hersey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bines</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McKinnon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Farma</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vidal-Sicart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoefer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Scheri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Nieweg</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Noyes</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hoon</surname>
                <given-names>DSB</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Elashoff</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Elashoff</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Jun</month>
            <day>08</day>
            <volume>376</volume>
            <issue>23</issue>
            <fpage>2211</fpage>
            <page-range>2211-2222</page-range>
            <pub-id pub-id-type="pmid">28591523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacKie</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Junor</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Feb</month>
            <day>06</day>
            <volume>348</volume>
            <issue>6</issue>
            <fpage>567</fpage>
            <page-range>567-8</page-range>
            <pub-id pub-id-type="pmid">12571271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crombie</surname>
                <given-names>IK</given-names>
              </name>
            </person-group>
            <article-title>Variation of melanoma incidence with latitude in North America and Europe.</article-title>
            <source>Br J Cancer</source>
            <year>1979</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>774</fpage>
            <page-range>774-81</page-range>
            <pub-id pub-id-type="pmid">508580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motofei</surname>
                <given-names>IG</given-names>
              </name>
            </person-group>
            <article-title>Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2019</year>
            <month>May</month>
            <day>06</day>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>45</fpage>
            <pub-id pub-id-type="pmid">31056729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motofei</surname>
                <given-names>IG</given-names>
              </name>
            </person-group>
            <article-title>Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches.</article-title>
            <source>Melanoma Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-236</page-range>
            <pub-id pub-id-type="pmid">30615013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byrne</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Immune and molecular correlates in melanoma treated with immune checkpoint blockade.</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>123</volume>
            <issue>S11</issue>
            <fpage>2143</fpage>
            <page-range>2143-2153</page-range>
            <pub-id pub-id-type="pmid">28543699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soufir</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Avril</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Chompret</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Demenais</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bombled</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spatz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stoppa-Lyonnet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>B&#x000e9;nard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bressac-de Paillerets</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.</article-title>
            <source>Hum Mol Genet</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>209</fpage>
            <page-range>209-16</page-range>
            <pub-id pub-id-type="pmid">9425228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puntervoll</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>XR</given-names>
              </name>
              <name>
                <surname>Vetti</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Bachmann</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Avril</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Benfodda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catrical&#x000e0;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duval-Modeste</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ghiorzo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grammatico</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Jouary</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Martin-Denavit</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ozola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pastorino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pjanova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Soufir</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Steine</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Stratigos</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tinat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tsao</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Veinalde</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bressac-de Paillerets</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Newton-Bishop</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Akslen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Molven</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.</article-title>
            <source>J Med Genet</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>4</issue>
            <fpage>264</fpage>
            <page-range>264-70</page-range>
            <pub-id pub-id-type="pmid">23384855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Hayward</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dracopoli</surname>
                <given-names>NC</given-names>
              </name>
            </person-group>
            <article-title>Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.</article-title>
            <source>Nat Genet</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-9</page-range>
            <pub-id pub-id-type="pmid">8528263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shattuck-Eidens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eeles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Gruis</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hussey</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Weaver-Feldhaus</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.</article-title>
            <source>Nat Genet</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-6</page-range>
            <pub-id pub-id-type="pmid">7987388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prota</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>d'Ischia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mascagna</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Melanogenesis as a targeting strategy against metastatic melanoma: a reassessment.</article-title>
            <source>Melanoma Res</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>351</fpage>
            <page-range>351-8</page-range>
            <pub-id pub-id-type="pmid">7703714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rastrelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tropea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Alaibac</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.</article-title>
            <source>In Vivo</source>
            <year>2014</year>
            <season>Nov-Dec</season>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>1005</fpage>
            <page-range>1005-11</page-range>
            <pub-id pub-id-type="pmid">25398793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gandini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Autier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Boniol</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Reviews on sun exposure and artificial light and melanoma.</article-title>
            <source>Prog Biophys Mol Biol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>107</volume>
            <issue>3</issue>
            <fpage>362</fpage>
            <page-range>362-6</page-range>
            <pub-id pub-id-type="pmid">21958910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vosm&#x000ed;k</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Malignant melanoma of the skin. Epidemiology, risk factors, clinical diagnosis].</article-title>
            <source>Cas Lek Cesk</source>
            <year>1996</year>
            <month>Jul</month>
            <day>26</day>
            <volume>135</volume>
            <issue>13</issue>
            <fpage>405</fpage>
            <page-range>405-8</page-range>
            <pub-id pub-id-type="pmid">8925536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lejeune</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and etiology of malignant melanoma.</article-title>
            <source>Biomed Pharmacother</source>
            <year>1986</year>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>91</fpage>
            <page-range>91-9</page-range>
            <pub-id pub-id-type="pmid">3527290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Neill</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Scoggins</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Melanoma.</article-title>
            <source>J Surg Oncol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>5</issue>
            <fpage>873</fpage>
            <page-range>873-881</page-range>
            <pub-id pub-id-type="pmid">31246291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uhara</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.</article-title>
            <source>Int J Clin Oncol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>12</issue>
            <fpage>1508</fpage>
            <page-range>1508-1514</page-range>
            <pub-id pub-id-type="pmid">29470725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtin</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fridlyand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kageshita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Busam</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kutzner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Aiba</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Br&#x000f6;cker</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>LeBoit</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Pinkel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bastian</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Distinct sets of genetic alterations in melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Nov</month>
            <day>17</day>
            <volume>353</volume>
            <issue>20</issue>
            <fpage>2135</fpage>
            <page-range>2135-47</page-range>
            <pub-id pub-id-type="pmid">16291983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poynter</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Elder</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Fullen</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Soengas</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Redman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>BRAF and NRAS mutations in melanoma and melanocytic nevi.</article-title>
            <source>Melanoma Res</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>267</fpage>
            <page-range>267-73</page-range>
            <pub-id pub-id-type="pmid">16845322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elder</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bastian</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Cree</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Massi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>144</volume>
            <issue>4</issue>
            <fpage>500</fpage>
            <page-range>500-522</page-range>
            <pub-id pub-id-type="pmid">32057276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Rigel</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kopf</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Lieblich</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Roses</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Gumport</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ragaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waldo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levenstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bart</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Trau</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi.</article-title>
            <source>Arch Dermatol</source>
            <year>1983</year>
            <month>Jun</month>
            <volume>119</volume>
            <issue>6</issue>
            <fpage>455</fpage>
            <page-range>455-62</page-range>
            <pub-id pub-id-type="pmid">6859885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smoller</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Histologic criteria for diagnosing primary cutaneous malignant melanoma.</article-title>
            <source>Mod Pathol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>19 Suppl 2</volume>
            <fpage>S34</fpage>
            <page-range>S34-40</page-range>
            <pub-id pub-id-type="pmid">16446714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abbasi</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Rigel</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Osman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kopf</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Polsky</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria.</article-title>
            <source>JAMA</source>
            <year>2004</year>
            <month>Dec</month>
            <day>08</day>
            <volume>292</volume>
            <issue>22</issue>
            <fpage>2771</fpage>
            <page-range>2771-6</page-range>
            <pub-id pub-id-type="pmid">15585738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniel Jensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>The ABCDEF Rule: Combining the "ABCDE Rule" and the "Ugly Duckling Sign" in an Effort to Improve Patient Self-Screening Examinations.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">25741397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holmes</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Vassantachart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Limone</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Zumwalt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hirokane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Using Dermoscopy to Identify Melanoma and Improve Diagnostic Discrimination.</article-title>
            <source>Fed Pract</source>
            <year>2018</year>
            <month>May</month>
            <volume>35</volume>
            <issue>Suppl 4</issue>
            <fpage>S39</fpage>
            <page-range>S39-S45</page-range>
            <pub-id pub-id-type="pmid">30766399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Sondak</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Faries</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Haydu</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Eggermont</surname>
                <given-names>AMM</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Balch</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
              <collab>for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform</collab>
            </person-group>
            <article-title>Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>67</volume>
            <issue>6</issue>
            <fpage>472</fpage>
            <page-range>472-492</page-range>
            <pub-id pub-id-type="pmid">29028110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayek</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dove</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Hunsinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shabahang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blansfield</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hospital-Based Study of Compliance with NCCN Guidelines and Predictive Factors of Sentinel Lymph Node Biopsy in the Setting of Thin Melanoma Using the National Cancer Database.</article-title>
            <source>Am Surg</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>672</fpage>
            <page-range>672-679</page-range>
            <pub-id pub-id-type="pmid">29966567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Janz</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Neskey</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lentsch</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Is imaging of the brain necessary at diagnosis for cutaneous head and neck melanomas?</article-title>
            <source>Am J Otolaryngol</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>631</fpage>
            <page-range>631-635</page-range>
            <pub-id pub-id-type="pmid">29929862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barker</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2018</year>
            <month>May</month>
            <volume>16</volume>
            <issue>5S</issue>
            <fpage>646</fpage>
            <page-range>646-650</page-range>
            <pub-id pub-id-type="pmid">29784747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reserva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Janeczek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Goslawski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Balasubramanian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Winterfield</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A Retrospective Analysis of Surveillance Adherence of Patients after Treatment of Primary Cutaneous Melanoma.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>44</fpage>
            <page-range>44-48</page-range>
            <pub-id pub-id-type="pmid">29399266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blakely</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Comissiong</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Vezeridis</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Suboptimal Compliance With National Comprehensive Cancer Network Melanoma Guidelines: Who Is at Risk?</article-title>
            <source>Am J Clin Oncol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>754</fpage>
            <page-range>754-759</page-range>
            <pub-id pub-id-type="pmid">28121641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coit</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Algazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andtbacka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bichakjian</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>DiMaio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gastman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guild</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Martini</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Materin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Olszanski</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Skitzki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swetter</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Torres-Roca</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Trisal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Urist</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>McMillian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Engh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Melanoma, Version 3.2016.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>945</fpage>
            <page-range>945-58</page-range>
            <pub-id pub-id-type="pmid">27496110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coit</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Algazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andtbacka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bichakjian</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>DiMaio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ernstoff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fields</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Fleming</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guild</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Halpern</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hodi</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Martini</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Materin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Olszanski</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Skitzki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sosman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swetter</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Tanabe</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Torres-Roca</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Trisal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Urist</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>McMillian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Engh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>450</fpage>
            <page-range>450-73</page-range>
            <pub-id pub-id-type="pmid">27059193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cascinelli</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Margin of resection in the management of primary melanoma.</article-title>
            <source>Semin Surg Oncol</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>272</fpage>
            <page-range>272-5</page-range>
            <pub-id pub-id-type="pmid">9588719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohn-Cedermark</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rutqvist</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Breivald</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ingvar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>J&#x000f6;nsson</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Krysander</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lindholm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ringborg</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm.</article-title>
            <source>Cancer</source>
            <year>2000</year>
            <month>Oct</month>
            <day>01</day>
            <volume>89</volume>
            <issue>7</issue>
            <fpage>1495</fpage>
            <page-range>1495-501</page-range>
            <pub-id pub-id-type="pmid">11013363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khayat</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rixe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Soubrane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Banzet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bazex</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lauret</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>V&#x000e9;rola</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Auclerc</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Banzet</surname>
                <given-names>P</given-names>
              </name>
              <collab>French Group of Research on Malignant Melanoma</collab>
            </person-group>
            <article-title>Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick).</article-title>
            <source>Cancer</source>
            <year>2003</year>
            <month>Apr</month>
            <day>15</day>
            <volume>97</volume>
            <issue>8</issue>
            <fpage>1941</fpage>
            <page-range>1941-6</page-range>
            <pub-id pub-id-type="pmid">12673721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karakousis</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Balch</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Urist</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bartolucci</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial.</article-title>
            <source>Ann Surg Oncol</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>446</fpage>
            <page-range>446-52</page-range>
            <pub-id pub-id-type="pmid">8876886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Newton-Bishop</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>A'Hern</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Coombes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Timmons</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Theaker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fallowfield</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ruka</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bliss</surname>
                <given-names>JM</given-names>
              </name>
              <collab>United Kingdom Melanoma Study Group</collab>
              <collab>British Association of Plastic Surgeons</collab>
              <collab>Scottish Cancer Therapy Network</collab>
            </person-group>
            <article-title>Excision margins in high-risk malignant melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Feb</month>
            <day>19</day>
            <volume>350</volume>
            <issue>8</issue>
            <fpage>757</fpage>
            <page-range>757-66</page-range>
            <pub-id pub-id-type="pmid">14973217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillgren</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Drzewiecki</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Niin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gullestad</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Hellborg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>M&#x000e5;nsson-Brahme</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ingvar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ringborg</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial.</article-title>
            <source>Lancet</source>
            <year>2011</year>
            <month>Nov</month>
            <day>05</day>
            <volume>378</volume>
            <issue>9803</issue>
            <fpage>1635</fpage>
            <page-range>1635-42</page-range>
            <pub-id pub-id-type="pmid">22027547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Utj&#x000e9;s</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Malmstedt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Teras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Drzewiecki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gullestad</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Ingvar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gillgren</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Aug</month>
            <day>10</day>
            <volume>394</volume>
            <issue>10197</issue>
            <fpage>471</fpage>
            <page-range>471-477</page-range>
            <pub-id pub-id-type="pmid">31280965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finley</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Driscoll</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Blumenson</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Karakousis</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Subungual melanoma: an eighteen-year review.</article-title>
            <source>Surgery</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>116</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-100</page-range>
            <pub-id pub-id-type="pmid">8023276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morton</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Cochran</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mozzillo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Elashoff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Essner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nieweg</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Roses</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Karakousis</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Reintgen</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Coventry</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Glass</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HJ</given-names>
              </name>
              <collab>MSLT Group</collab>
            </person-group>
            <article-title>Sentinel-node biopsy or nodal observation in melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Sep</month>
            <day>28</day>
            <volume>355</volume>
            <issue>13</issue>
            <fpage>1307</fpage>
            <page-range>1307-17</page-range>
            <pub-id pub-id-type="pmid">17005948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morton</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Cochran</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mozzillo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nieweg</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Roses</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Karakousis</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Puleo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Coventry</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Kashani-Sabet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smithers</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kraybill</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>McKinnon</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Elashoff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Faries</surname>
                <given-names>MB</given-names>
              </name>
              <collab>MSLT Group</collab>
            </person-group>
            <article-title>Final trial report of sentinel-node biopsy versus nodal observation in melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Feb</month>
            <day>13</day>
            <volume>370</volume>
            <issue>7</issue>
            <fpage>599</fpage>
            <page-range>599-609</page-range>
            <pub-id pub-id-type="pmid">24521106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luke</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Queirolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mackiewicz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chiarion-Sileni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>de la Cruz Merino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Khattak</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mandala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Galitiis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haydon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carlino</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Poklepovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sondak</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Diede</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ahsan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eggermont</surname>
                <given-names>AMM</given-names>
              </name>
              <collab>KEYNOTE-716 Investigators</collab>
            </person-group>
            <article-title>Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2022</year>
            <month>Apr</month>
            <day>30</day>
            <volume>399</volume>
            <issue>10336</issue>
            <fpage>1718</fpage>
            <page-range>1718-1729</page-range>
            <pub-id pub-id-type="pmid">35367007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Luke</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Khattak</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>de la Cruz Merino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spagnolo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mackiewicz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chiarion-Sileni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>de Galitiis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carlino</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Fukunaga-Kalabis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krepler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eggermont</surname>
                <given-names>AMM</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <collab>KEYNOTE-716 Investigators</collab>
            </person-group>
            <article-title>Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>1378</fpage>
            <page-range>1378-1388</page-range>
            <pub-id pub-id-type="pmid">36265502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garbe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keim</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Suciu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amaral</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eigentler</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Gesierich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hauschild</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heinzerling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kiecker</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sunderk&#x000f6;tter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>T&#x000fc;ting</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Utikal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wollina</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zouboulis</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Keilholz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Testori</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martus</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Eggermont</surname>
                <given-names>AMM</given-names>
              </name>
              <collab>German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer</collab>
            </person-group>
            <article-title>Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>38</volume>
            <issue>22</issue>
            <fpage>2543</fpage>
            <page-range>2543-2551</page-range>
            <pub-id pub-id-type="pmid">32530760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moncrieff</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Heaton</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Nobes</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Snelling</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Nessim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peach</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kisyova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pritchard Jones</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johansson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Olofsson Bagge</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Sondak</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Zager</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.</article-title>
            <source>J Clin Oncol</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>40</volume>
            <issue>34</issue>
            <fpage>3940</fpage>
            <page-range>3940-3951</page-range>
            <pub-id pub-id-type="pmid">35849790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mandala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gogas</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Arance</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Cowey</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schenker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiarion-Sileni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marquez-Rodas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Maio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Queirolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kudchadkar</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Smylie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mortier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lebb&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yokota</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>de Pril</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sabater</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <collab>CheckMate 238 Collaborators</collab>
            </person-group>
            <article-title>Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>09</day>
            <volume>377</volume>
            <issue>19</issue>
            <fpage>1824</fpage>
            <page-range>1824-1835</page-range>
            <pub-id pub-id-type="pmid">28891423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hauschild</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santinami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mandal&#x000e0;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chiarion Sileni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nyakas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dutriaux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haydon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mortier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schachter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lesimple</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Plummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dasgupta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gasal</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Sep</month>
            <day>17</day>
            <volume>383</volume>
            <issue>12</issue>
            <fpage>1139</fpage>
            <page-range>1139-1148</page-range>
            <pub-id pub-id-type="pmid">32877599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eggermont</surname>
                <given-names>AMM</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Mandala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dalle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haydon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lichinitser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khattak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlino</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larkin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ascierto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rutkowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schadendorf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koornstra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hernandez-Aya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van den Eertwegh</surname>
                <given-names>AJM</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gutzmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jamal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lorigan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marreaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Akkooi</surname>
                <given-names>ACJ</given-names>
              </name>
              <name>
                <surname>Suciu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>May</month>
            <day>10</day>
            <volume>378</volume>
            <issue>19</issue>
            <fpage>1789</fpage>
            <page-range>1789-1801</page-range>
            <pub-id pub-id-type="pmid">29658430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burmeister</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ainslie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Di Iulio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smithers</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Carruthers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coventry</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Babington</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duprat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>589</fpage>
            <page-range>589-97</page-range>
            <pub-id pub-id-type="pmid">22575589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henderson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Burmeister</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Ainslie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Di Iulio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smithers</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Carruthers</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coventry</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Babington</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duprat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoekstra</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>1049</fpage>
            <page-range>1049-1060</page-range>
            <pub-id pub-id-type="pmid">26206146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Othus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Yost</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hyngstrom</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hu-Lieskovan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lao</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Fecher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Eisenstein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sosman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kendra</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Devoe</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Hegde</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mangla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reese</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Poklepovic</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>GQ</given-names>
              </name>
              <name>
                <surname>Onitilo</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Yasar</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Doolittle</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>In</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Kokot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gibney</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Shaheen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Warneke</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ikeguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Najera</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Chmielowski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Crompton</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Floyd</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hsueh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Margolin</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Grossmann</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Korde</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sharon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sondak</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Ribas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Mar</month>
            <day>02</day>
            <volume>388</volume>
            <issue>9</issue>
            <fpage>813</fpage>
            <page-range>813-823</page-range>
            <pub-id pub-id-type="pmid">36856617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24678.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reijers</surname>
                <given-names>ILM</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>van Akkooi</surname>
                <given-names>ACJ</given-names>
              </name>
              <name>
                <surname>Versluis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>NMJ</given-names>
              </name>
              <name>
                <surname>Saw</surname>
                <given-names>RPM</given-names>
              </name>
              <name>
                <surname>Pennington</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Kapiteijn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van der Veldt</surname>
                <given-names>AAM</given-names>
              </name>
              <name>
                <surname>Suijkerbuijk</surname>
                <given-names>KPM</given-names>
              </name>
              <name>
                <surname>Hospers</surname>
                <given-names>GAP</given-names>
              </name>
              <name>
                <surname>Rozeman</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Klop</surname>
                <given-names>WMC</given-names>
              </name>
              <name>
                <surname>van Houdt</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Sikorska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van der Hage</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nhagen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Wouters</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Witkamp</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Zuur</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Lijnsvelt</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Torres Acosta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grijpink-Ongering</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>J&#x000f3;&#x0017a;wiak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bierman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Ch'ng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Colebatch</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Spillane</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Haanen</surname>
                <given-names>JBAG</given-names>
              </name>
              <name>
                <surname>Rawson</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>van de Wiel</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>van de Poll-Franse</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Boekhout</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Blank</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.</article-title>
            <source>Nat Med</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>1178</fpage>
            <page-range>1178-1188</page-range>
            <pub-id pub-id-type="pmid">35661157</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
